Pibarot's laboratory


Philippe Pibarot

Dr. Philippe Pibarot heads the Canada Research Chair in Valvular Heart Diseases at the University Institute of Cardiology and Pneumology of Quebec and is a professor at the Faculty of Medicine of Laval University. After completing his studies in veterinary medicine in 1987 at the Claude Bernard University in Lyon in France, Dr Pibarot immigrated in Quebec where he obtained a PhD degree in the field of cardiovascular sciences at the University of Montreal in 1995. He joined Laval Hospital and Laval University in 1998 where he established his research laboratory on diseases affecting heart valves.

The research projects led by Dr Pibarot and his team aim to elucidate the mechanisms governing heart valve diseases and to design new pharmacological, surgical or percutaneous approaches to improve the treatment of these diseases. In particular, Dr. Pibarot's team has made an important contribution to improving the diagnosis and treatment of low-flow, low-gradient aortic stenosis which poses significant challenges. Their research on this subject has influenced the practice guidelines. Dr. Pibarot's team has also made a significant contribution to the validation and advancement of valve catheter therapy. The IUCPQ is one of the world's leading centers of excellence for this technology, which has revolutionized the treatment of valve disease.

Dr. Pibarot leads several large research projects involving more than 100 hospitals and universities in Canada and other countries. These projects are funded by the Canadian Institutes of Health Research and by research contracts with industry. Dr Pibarot has published over 650 scientific papers and presented over 1000 guest lectures in many countries during his career.

Mission and projects

The mission is to develop new approaches for improving the diagnosis, prevention and treatment of heart valve disease.

Clinical trial: PARTNER 2 –SAPIEN 3, which aims to evaluate the efficacy and safety of the SAPIEN 3 percutaneous aortic valve in 1500 patients for the treatment of patients with severe aortic stenosis and moderate to high risk of surgery. https://clinicaltrials.gov/ct2/show/NCT01314313

– Essai clinique PARTNER 3 qui randomise les patients (1200 dans >60 centres) à bas risque chirurgical entre RVA chirurgical et RVA percutané au moyen de la valve SAPIEN 3. https://clinicaltrials.gov/ct2/show/NCT02675114

– EARLY-TAVR qui teste l’effet du moment (précoce versus à l’apparition des symptômes) du RVA par cathéter chez les patients (1000 dans >60 centres) asymptomatiques avec sténose aortique sévère. https://clinicaltrials.gov/ct2/show/NCT03042104

Clinical trial: TAVR-UNLOAD, which test the effect of catheter aortic valve replacement (AVR) in 600 patients with moderate stenosis and systolic heart failure. https://clinicaltrials.gov/ct2/show/NCT02661451

– Essai clinique V-Wave qui vise à évaluer l’efficacité et la sécurité du dispositif implantable V-Wave qui crée un shunt restrictif gauche-droit dans le septum inter-auriculaire pour le traitement de l’insuffisance cardiaque gauche réfractaire au traitement médical. http://vwavemedical.com/

– Essai clinique BACE qui l’efficacité et la sécurité du dispositif implantable BACE (Cardiac Phoenix) qui crée un shunt restrictif gauche-droit dans le septum inter-auriculaire pour le traitement de l’insuffisance cardiaque gauche réfractaire au traitement médical. http://www.phoenixcardiac.com/bace-device/

EN